FindTrial
Sign In

The efficacy and safety of concurrent/sequential chemoradiotherapy and immunoconsolidation therapy for stage III non-resectable non-small cell lung cancer after chemoimmunotherapy induction therapy: a single center, retrospective study

The efficacy and safety of concurrent/sequential chemoradiotherapy and immunoconsolidation therapy for stage III non-resectable non-small cell lung cancer after chemoimmunotherapy induction therapy: a single center, retrospective study

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109092
Enrollment
Unknown
Registered
2025-09-11
Start date
2024-06-01
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage III non-resectable non-small cell lung cancer

Interventions

Treatment:NA

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.ECOGPS 0-1; 2.18-75 years old; 3.Histologically or cytologically confirmed stage III NSCLC; 4.Unresectable disease, no prior systemic therapy for stage III NSCLC or treatment with immune checkpoint inhibitors,unresectable.

Exclusion criteria

Exclusion criteria: 1.Patients with early or advanced disease; 2.Patients with a previous history of other tumors; 3.Patients with contraindications to chemotherapy, immunotherapy, radiotherapy or those who refuse the above treatments; 4.Any prior systematic treatment.

Design outcomes

Primary

MeasureTime frame
1 year PFS ratio;—

Countries

China

Contacts

Public ContactXu Shuangbing

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

xsb723@hust.edu.cn+86 15927265462

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026